(Total Views: 646)
Posted On: 12/25/2020 12:51:23 AM
Post# of 153827
Well lets hope the analysis of that NEJM article is correct.
It gives roughly 15 serious reasons why expanded access wont work.
14 of the failure factors do not apply to CYDY/leronlimab.
Its like they set out to make a list of problems that do not apply to CYDY/leronlimab
There is that last problematic item. 120 man hours of work at Cytodyn needed to support the expanded access. Well, they have got 20 guys there at Cytodyn. Maybe they can divide up the work so they get it done by noon Monday
It gives roughly 15 serious reasons why expanded access wont work.
14 of the failure factors do not apply to CYDY/leronlimab.
Its like they set out to make a list of problems that do not apply to CYDY/leronlimab
There is that last problematic item. 120 man hours of work at Cytodyn needed to support the expanded access. Well, they have got 20 guys there at Cytodyn. Maybe they can divide up the work so they get it done by noon Monday
(3)
(0)
